AR030414A1 - Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos - Google Patents

Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos

Info

Publication number
AR030414A1
AR030414A1 ARP010101322A ARP010101322A AR030414A1 AR 030414 A1 AR030414 A1 AR 030414A1 AR P010101322 A ARP010101322 A AR P010101322A AR P010101322 A ARP010101322 A AR P010101322A AR 030414 A1 AR030414 A1 AR 030414A1
Authority
AR
Argentina
Prior art keywords
combination
formulation
pharmaceutical
hmg
nipololol
Prior art date
Application number
ARP010101322A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0001188A external-priority patent/SE0001188D0/xx
Priority claimed from SE0002352A external-priority patent/SE0002352D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR030414A1 publication Critical patent/AR030414A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Una combinacion farmacéutica que comprende una beta bloqueante y un inhibidor de la HMG-CoA reductasa, donde el beta bloqueante se selecciona del grupo consistente en: acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufuralol, bunitrolol, buprandolol, butofilolol, carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, indenolol, labetalol, levobunolol, mepindolol, metipranolol, metoprolol, nadolol, nadoxolol, nebivalol, nipradilol, oxprenolol, perbutolol, pindolol, practolol, pronetalol, propanolol, sotalol, sufinalol, talindol, tertatolol, tilisolol, timolol, toliprolol y xibenolol, y las sales o solvatos farmacéuticamente aceptables de los mismos, o los solvatos de dichas sales; y el inhibidor de la HMG-CoA reductasa se selecciona del grupo consistente en: cerivastatina, itavastatina, lovastatina, mevastatina, nicostatina, nivastatina y ácido (E)-7[ 4-(4-fluorfenil)-6-isopropil-2-[metil(metilsulfonil)amino]-pirimidin-5-il](3R.5S)-3,5-dihidroxihept-6-enoico o una sal o solvato farmacéuticamente aceptable del mismo, o un solvato de dicha sal, util para el tratamiento profiláctico o terapéutico de la aterosclerosis, y hipercolesterolemia e hiperlipoproteinemia; formulacion farmacéutica, equipo transportable de partes, uso de esta combinacion y de esta formulacion para preparar medicamentos.
ARP010101322A 2000-04-03 2001-03-21 Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos AR030414A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0001188A SE0001188D0 (sv) 2000-04-03 2000-04-03 New combination
SE0002352A SE0002352D0 (sv) 2000-06-22 2000-06-22 New combination

Publications (1)

Publication Number Publication Date
AR030414A1 true AR030414A1 (es) 2003-08-20

Family

ID=26655059

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101322A AR030414A1 (es) 2000-04-03 2001-03-21 Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos

Country Status (25)

Country Link
US (2) US20030060477A1 (es)
EP (1) EP1272219B1 (es)
JP (1) JP2003528928A (es)
KR (1) KR20020086749A (es)
CN (1) CN1422161A (es)
AR (1) AR030414A1 (es)
AT (1) ATE347909T1 (es)
AU (2) AU2001242985B2 (es)
BR (1) BR0109753A (es)
CA (1) CA2403160A1 (es)
DE (1) DE60125159T2 (es)
EE (1) EE200200570A (es)
ES (1) ES2276774T3 (es)
HK (1) HK1051325A1 (es)
HU (1) HUP0300332A3 (es)
IL (1) IL151589A0 (es)
IS (1) IS6554A (es)
MX (1) MXPA02009705A (es)
MY (1) MY136386A (es)
NO (1) NO20024732D0 (es)
NZ (1) NZ521351A (es)
PL (1) PL357813A1 (es)
RU (1) RU2002123591A (es)
SK (1) SK14102002A3 (es)
WO (1) WO2001074394A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
ITMI20040145A1 (it) * 2004-01-30 2004-04-30 Acraf L-moprololo lpiu' tartrato
EP1722758A1 (en) * 2004-02-11 2006-11-22 Athpharma Limited Chronotherapeutic compositions and methods of their use
ATE525354T1 (de) * 2004-05-03 2011-10-15 Janssen Pharmaceutica Nv Benzofuranderivate als selektive androgenrezeptormodulatoren (sarms)
CN101022791B (zh) * 2004-06-04 2011-11-16 麦兰实验室公司 含奈必洛尔的组合物
WO2008015763A1 (fr) 2006-08-04 2008-02-07 Aska Pharmaceutical Co., Ltd. Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
CN102462844A (zh) * 2010-11-05 2012-05-23 四川滇虹医药开发有限公司 一种替利洛尔的药物组合物及其制备方法
WO2013157833A1 (ko) * 2012-04-18 2013-10-24 서울대학교산학협력단 베타-차단제를 유효성분으로 포함하는 비만, 비만으로 인한 대사성 질환 및 골감소증 예방, 개선 또는 치료용 조성물
CN103613586B (zh) * 2013-11-01 2016-06-08 北京博爱旺康医药科技有限公司 一种旋光纯s-(-)-阿罗洛尔酸式盐及其制备方法和应用
CN103626750B (zh) * 2013-11-15 2016-02-24 北京博爱旺康医药科技有限公司 一种盐酸阿罗洛尔及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175187A (en) * 1989-03-06 1992-12-29 Soorianarain Baligadoo Synergistic compositions for the treatment of coronary insufficiency and methods of use thereof
US5455269A (en) * 1989-03-06 1995-10-03 Baligadoo; Soorianarain Synergistic compositions of amiodarone and beta blockers
DK0576617T3 (da) * 1991-03-18 1996-12-30 Sepracor Inc Præparat og fremgangsmåde indeholdende optisk rent (S) metoprolol
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
NO177455C (no) * 1993-06-04 1995-09-20 Gerrit Elmenhorst Anordning ved apparat for fremstilling av brannslukkende skum
JP2000508659A (ja) * 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
SE9602762D0 (sv) * 1996-07-12 1996-07-12 Astra Ab Carton and blank for forming the same
US5998458A (en) * 1997-06-25 1999-12-07 University Technology Corporation Method of treating heart failure
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
BR9916564A (pt) * 1998-12-23 2002-01-29 Searle Llc Combinações para indicações cardiovasculares

Also Published As

Publication number Publication date
HUP0300332A2 (hu) 2003-06-28
IL151589A0 (en) 2003-04-10
MY136386A (en) 2008-09-30
NO20024732L (no) 2002-10-02
JP2003528928A (ja) 2003-09-30
BR0109753A (pt) 2003-02-04
SK14102002A3 (sk) 2003-06-03
EP1272219B1 (en) 2006-12-13
HK1051325A1 (en) 2003-08-01
NZ521351A (en) 2004-08-27
US20040192784A1 (en) 2004-09-30
DE60125159T2 (de) 2007-10-25
CN1422161A (zh) 2003-06-04
KR20020086749A (ko) 2002-11-18
PL357813A1 (en) 2004-07-26
IS6554A (is) 2002-09-19
EE200200570A (et) 2004-04-15
MXPA02009705A (es) 2004-02-26
ATE347909T1 (de) 2007-01-15
RU2002123591A (ru) 2004-03-20
CA2403160A1 (en) 2001-10-11
WO2001074394A1 (en) 2001-10-11
NO20024732D0 (no) 2002-10-02
DE60125159D1 (de) 2007-01-25
US20030060477A1 (en) 2003-03-27
WO2001074394A8 (en) 2002-05-23
HUP0300332A3 (en) 2005-03-29
ES2276774T3 (es) 2007-07-01
AU2001242985B2 (en) 2005-02-24
EP1272219A1 (en) 2003-01-08
AU4298501A (en) 2001-10-15

Similar Documents

Publication Publication Date Title
AR030414A1 (es) Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
IL156167A (en) Compounds of ABCA-1 for use in the preparation of a pharmacological preparation for the treatment of diseases following arterio-sclerosis
RU2002124873A (ru) Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
US20030171416A1 (en) Method for treatment of tumors using nordihydroguaiaretic acid derivatives
DE60008608D1 (de) Stabilisierte pharmazeutisch wirksame zubereitung und diese enthaltende arzneizusammensetzung
HRP20120006T1 (hr) Derivat bicikloestera
PT812588E (pt) Composicao farmaceutica externa para administracao topica contendo 2-amino-2-(2-(4-octilfenil)-etil)-propano-1,3-diol para o tratamento de doencas provocadas por uma afeccao imunitaria
DE69937691D1 (de) Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin
DE69712877D1 (de) Zyklischaminosäure als pharmazeutische mittel
IT1314184B1 (it) Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
ECSP024386A (es) INHIBIDORES DE HMG-Co REDUCTASA Y SU EMPLEO COMO MEDICAMENTO EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON EL COLESTEROL
DE68914687T2 (de) Hydroxamsäure enthaltende collagenase-inhibitoren.
CZ2004337A3 (cs) Způsob přípravy vápenatých solí statinů
ATE210629T1 (de) Verbrückte zyklische aminosäuren als pharmazeutische mittel
KR970705990A (ko) 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
DE69811905T2 (de) Cyclohexenon langketten alkohol und diese enthaltendes arzneimittel
Hu et al. Peptidyl hydroxamic acids as methionine aminopeptidase inhibitors
DK1150667T3 (da) Langkædet cyclohexenonalkohol til behandling af amytrofisk lateralsklerose
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
ATE333897T1 (de) Arzneimittel mit chymaseinhibitoren als wirksames mittel zur behandlung von dermatitis mit zweiphasigen hautreaktionen
Whitfield Statins: new drugs for treating osteoporosis?
GB2371748A (en) HMG-COA reductase inhibitor extended release formulation
KR960703843A (ko) 아실페닐글리신 유도체 및 그 화합물을 유효성분으로 하는, 콜라게나제 활성증진에 기인한 질환의 예방 및 치료 제(acylphenylglycine derivative and preventive and remedy for diseases caused by increased collagenase activity containing said compound as active ingredient)
ES2096208T3 (es) Derivados de octahidronaftaleno oxima para la inhibicion de la biosintesis de colesterol, su preparacion y utilizacion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure